This company develops and markets FDA-approved drugs, focusing on essential hypertension, with a commitment to addressing needs in the rare disease space.
0
Orphan Designations
7
FDA Approvals
Latest: SPIRONOLACTONE (2017)
0
Active Trials
1
Rare Diseases
across 1 areas
0
News (30d)
Quiet
Padagis US LLC is a company with 0 orphan drug designations across 1 rare disease, including 7 FDA-approved therapies.
Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.
Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA
| Disease | Drug(s) | Stage |
|---|---|---|
| essential hypertension | AMILORIDE HYDROCHLORIDE | Des.TrialAppr. |
0% of portfolio targets high unmet need diseases
0
overlap in 2+ diseases
0/1
candidate diseases
0
avg importance: 0
0
affecting portfolio
0% of portfolio targets high unmet need diseases
0
overlap in 2+ diseases
0/1
candidate diseases
0
avg importance: 0
0
affecting portfolio